|
11. |
Continuous-Infusion High-Dose Leucovorin With 5-Fluorouracil and Cisplatin for Relapsed Metastatic Breast Cancer: A Phase II Study |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 40-41
Daniel Booser,
Ronald Walters,
Frankie Holmes,
Gabriel Hortobagyi,
Preview
|
|
摘要:
Twelve women with metastatic breast cancer were treated with continuous infusion high dose leucovorin, 5-fluorouracil and cisplatin. Toxicity was severe although the dose was lower than previously described for the treatment of other cancers, and there was little anti-tumor activity. Many other regimens are more effective and less toxic.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
12. |
Pyomyositis After Chemotherapy for Breast Cancer |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 42-44
Bruce Keith,
Vivien Bramwell,
Preview
|
|
摘要:
Pyomyositis is a rare complication of chemotherapy.A 47-year-old woman with metastatic breast cancer, in whom pyomyositis developed after chemotherapy, is described. It was difficult to differentiate between pyomyositis and deep venous thrombosis early in her admission. Pyomyositis should be considered part of the differential diagnosis of deep venous thrombosis. This infection, after chemotherapy, usually is considered to be caused by neutropenia or immunodeficiency secondary to the cancer, or both. It is postulated that subclinical myopathy, secondary to the malignancy or drugs used in treating the malignancy, or both, may also predispose to pyomyositis.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
13. |
Treatment of Squamous Cell Esophageal Cancer With TopotecanAn Eastern Cooperative Oncology Group Study (E2293) |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 45-46
Robert Asbury,
Stuart Lipsitz,
David Graham,
Carla Falkson,
Luis Baez,
Al Benson,
Preview
|
|
摘要:
Seventeen patients with enhanced measurable squamous cell carcinoma of the esophagus were treated with topotecan 1.5 mg/m2daily for 5 days repeated every 21 days. Toxicity was severe, with 1 death from myelotoxicity and 10 patients with life-threatening myelotoxicity. Severe gastrointestinal toxicity consisting of vomiting was also seen in three patients. No response was seen in any of the patients in the study. Topotecan given in this manner has no activity in squamous cell carcinoma of the esophagus.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
14. |
Accuracy and Clinical Impact of Mediastinal Lymph Node Staging with FDG–PET Imaging in Potentially Resectable Lung Cancer |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 47-52
Elaine Weng,
Luu Tran,
Sheila Rege,
Afshin Safa,
Ahmad Sadeghi,
Guy Juillard,
Rufus Mark,
Silverio Santiago,
Charles Brown,
Mark Mandelkern,
Preview
|
|
摘要:
To determine the sensitivity, specificity, and accuracy of staging mediastinal nodal disease in potentially resectable lung cancer using fluorodeoxyglucose–positron emission tomography (FDG–PET), computed tomography (CT), or both and compare these results to surgical staging. We also assessed whether PET scanning results changed clinical management. From 1992 to 1997, 50 patients underwent CT, and PET scanning before or close to the time of surgical staging. Sensitivity, specificity, accuracy, and predictive values were then calculated based on pathology results. A retrospective review of the records was performed to determine how PET results affected clinical treatment decisions. Forty-seven of 50 patients had non–small-cell lung cancer. The prevalence of pathologically confirmed mediastinal and hilar involvement was 38%. The sensitivity, specificity, and accuracy of mediastinal disease staging were as follows: CT alone = 73%, 77%, 76%; PET alone = 73%, 94%, 87%; PET + CT = 82%, 96%, 91%, respectively. PET was more specific and accurate than CT (p = 0.025). The results of PET changed management decisions in 12 of 50 cases (24%). Using FDG–PET in conjunction with CT scanning provides the most accurate staging of mediastinal disease in lung cancer by contributing complementary information. Furthermore, PET can affect clinical decision-making and allow some patients considered unresectable a chance for resection.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
15. |
The Roles of Chemotherapy and Surgery in Gastric Carcinoma and the Influence of Prognostic Factors on Survival |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 53-57
Faruk Tas,
N. Aykan,
Adnan Aydiner,
Kazim Uygun,
Mert Basaran,
Hakan Camlica,
Erkan Topuz,
Preview
|
|
摘要:
In this study, we present the results of surgery and chemotherapy and the impact of various prognostic factors on survival in patients with gastric carcinoma with a follow-up of 6 years. All of the 328 cases were adenocarcinoma histologically and had a median age of 55 years. Median survival was 11 months, and the 5-year survival rate was 18%. Nonmetastatic cases were associated with improved survival as compared with the cases with metastatic disease (p< 0.001). Patients with gastrectomy had improved survival (p< 0.001). Subtotal gastrectomized patients had better survival rates in comparison to the total gastrectomized patients (p= 0.03). Addition of splenectomy to total gastrectomy and adjuvant chemotherapy did not influence survival rates (p> 0.05). In metastatic patients, we determined beneficial effects of gastrectomy and chemotherapy on survival. The benefit was most predominant in chemoresponsive patients (p< 0.001). Higher serum CA 19.9 levels in patients without metastases, higher serum lactate dehydrogenase and carcinoembryonic antigen levels in patients with metastases, and lower serum albumin levels in both stages were determined as significant predictors of poor survival. On multivariate analysis, only higher serum CA 19.9 level was the independent unfavorable prognostic factor of survival time in nonmetastatic patients (p= 0.008). In metastatic disease, older age (p= 0.03) and male gender (p= 0.05) were associated with poorer survival. In conclusion, gastric cancer is a great health problem, especially in developing countries, and we need more optimal approaches and treatment modalities for gastric cancer.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
16. |
Poorly Differentiated Carcinoma of the Lung Presenting With Lambert—Eaton Myasthenic Syndrome |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 58-59
Sreejith Nair,
B. Kumar,
Balakrishnan Rajan,
Preview
|
|
摘要:
Lambert–Eaton myasthenic syndrome commonly seen in small-cell lung cancer represents an autoimmune reaction against antigens coexpressed by tumor and neurons. It is rarely seen with other histologic subtypes. Symptoms antedate the appearance of the neoplasm by weeks to years. Therapeutic options range from immunosuppression, plasmapheresis, pharmacologic facilitation of neuromuscular transmission, and definitive therapy of the primary tumor. This case report describes the rare association of Lambert–Eaton myasthenic syndrome with non–small-cell lung cancer.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
17. |
A Phase II Trial of Vinorelbine and Cisplatin in Previously Untreated Inoperable Non—Small-Cell Lung Cancer |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 60-64
Reury-P. Perng,
Jen-F. Shih,
Yuh-M. Chen,
Francois Delgado,
Chun-M. Tsai,
Kuo-C. Chou,
Jacqueline Liu,
Ming-S. Chern,
Jacqueline Whang-Peng,
Preview
|
|
摘要:
Weekly vinorelbine injection with cisplatin had been used in treatment of non–small-cell lung cancer. We performed a phase II trial to evaluate the efficacy and toxicity of a new schedule of vinorelbine and cisplatin in patients with previously untreated, inoperable (stage IIIB or stage IV) non–small-cell lung cancer. From April 1996 to May 1997, 52 patients were enrolled for study, and 50 patients were eligible and evaluable for both response and toxicity assessment. Therapy consisted of vinorelbine, 30 mg/m2, intravenously on days 1 and 5 of a 21-day cycle, and cisplatin 100 mg/m2(reduced to 80 mg/m2after the first seven patients) given on day 1. A total of 211 treatment courses were administered; the median number of cycles administered per patient was 4.5 (range: 1–6), the median dose intensity for vinorelbine was 16.9 mg/m2/week (84.4%), whereas that of cisplatin was 22.8 mg/m2/week (84.7%). Twenty-five patients responded to therapy for an overall response rate of 50%; one patient attained a complete response (2%). The main toxicities were vomiting, myelosuppression, and diarrhea, which included World Health Organization grade 3 or 4 nausea/vomiting (58% patients), anemia (41% patients), neutropenia (12% patients), and diarrhea (14%). The median duration of responses was 9 months. The median time to disease progression was 6.8 months (range 0.4–18.1 months). Median survival was 13 months, and 54% of patients were alive at 1 year. We conclude that this new schedule of vinorelbine and cisplatin achieves a high response with acceptable toxicity profile in patients with advanced non–small-cell lung cancer.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
18. |
Oral Etoposide for Merkel Cell Carcinoma in Patients Previously Treated With Intravenous Etoposide |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 65-67
Eyal Fenig,
Baruch Brenner,
Eliud Njuguna,
Alan Katz,
Jacob Schachter,
Aaron Sulkes,
Preview
|
|
摘要:
We describe three patients with advanced Merkel cell carcinoma who were treated with etoposide given orally for recurrent regional lymph node involvement 18 to 30 months after exposure to etoposide given intravenously. Etoposide given orally (100 mg/day) was given for 10 to 14 consecutive days and repeated every 21 to 28 days for a median of three courses (range: two to four). Toxicity was minimal and mainly hematologic. Two patients showed a complete response and one a partial response, all of very rapid onset. All three patients are alive 6, 9, and 42 months from the start of oral treatment. Two remain progression free, and one had a recurrence 1 month after completion of chemotherapy. We suggest that orally administered etoposide, a topoisomerase II inhibitor, has a strong antitumor effect in advanced Merkel cell carcinoma, even in patients previously treated parenterally with the same drug. This action may be explained by the greater dependence of the drug’s efficacy on the duration of administration rather than the dose intensity.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
19. |
Phase II Study of Doxorubicin and Paclitaxel as Second-Line Chemotherapy of Small-Cell Lung CancerA Hoosier Oncology Group Trial |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 68-70
Gura Sonpavde,
Rafat Ansari,
Paul Walker,
David Sciortino,
G. Gabrys,
Ann Murdock,
René Gonin,
Lawrence Einhorn,
Preview
|
|
摘要:
Forty-six evaluable patients with recurrent small-cell lung cancer were entered on a phase II Hoosier Oncology Group (HOG) protocol evaluating bolus doxorubicin 40 mg/m2followed by paclitaxel 175 mg/m2over 3 hours. Courses were repeated every 3 weeks for a maximum of 6 courses. Therapy was well-tolerated with grade III neurotoxicity in 5 patients (11%), grade III/IV emesis in 5 (11%), and grade III mucositis in 2 patients. One patient had grade IV myalgias and one patient had grade III cardiotoxicity. The main toxicity was myelosuppression. Twenty-nine patients (63%) had grade IV and 8 (17%) grade III granulocytopenia. Nine patients (20%) were hospitalized for granulocytopenic fever. There was no treatment-related mortality. Nineteen of 46 patients (41%) had an objective response, including 3 complete remissions. Two of 14 patients with refractory disease (progression less than 3 months after initial therapy) responded, compared to 17 of 32 (52%) with sensitive disease (progression beyond 3 months of initial chemotherapy regimen).
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
20. |
Warfarin Is Safe as Secondary Prophylaxis in Patients With Cancer and a Previous Episode of Venous Thrombosis |
|
American Journal of Clinical Oncology: Cancer Clinical Trials,
Volume 23,
Issue 1,
2000,
Page 71-73
Robert Bona,
Amy Hickey,
Donna Wallace,
Preview
|
|
摘要:
The purpose of this study was to establish the safety and efficacy of sodium warfarin in the secondary prophylaxis of venous thrombosis in patients with cancer. This was an inception cohort study of patients enrolled in an anticoagulation clinic between July 1991 and October 1996. The rates of bleeding and recurrent thrombosis were evaluated in all the patients, and the results in patients with cancer (n = 104) were compared with those without cancer (n = 208). The rate of major hemorrhage was 0.4% and 0.3% per treatment month in the patients with cancer and those without cancer, respectively. The rates of recurrent thrombosis were 1.2% and 0.2% per treatment month in the patients with cancer compared with those without cancer, respectively. We conclude that warfarin is safe when used for the secondary prophylaxis of patients with cancer who have had a venous or arterial thrombosis, and the risk of major hemorrhage is not significantly different when compared with the risk in patients without cancer. The rate of recurrent thrombosis is approximately sixfold higher in patients with cancer being treated with warfarin for secondary prophylaxis of thrombosis compared with patients without cancer. Nonetheless, the rate of recurrent thrombosis is not overly excessive, and warfarin can be viewed as a relatively effective form of therapy for these patients.
ISSN:0277-3732
出版商:OVID
年代:2000
数据来源: OVID
|
|